Published on July 22, 2010 at 3:46 AM
Tamir Biotechnology, Inc. (formerly Alfacell Corporation) (OTCBB:ACEL) announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) confirmed that testing of two (2) of the company's compounds Onconase® (Ranpirnase), and recombinant Amphinase 2 showed positive in vitro results for Severe Acute Respiratory Syndrome, also known as (SARS) virus.
In order to determine the effectiveness of a compound, NIAID uses a Selectivity Index (SI). The SI measures EC50 (50% virus-inhibitory (effective) concentration and EC90 (90%) cell inhibitory (cytotoxic) concentration determined in stationary cells.
"Many companies spend years in research and development and untold millions in the hope of developing a compound capable of demonstrating anti viral activity against a single virus. This week we've been able to report positive anti viral activity in Dengue stated Charles Muniz, Chief Executive Officer of Tamir.
SOURCE Tamir Biotechnology, Inc.
92fbe908-58a6-485e-841b-4c92330c4838|0|.0
Posted in: Disease/Infection News | Pharmaceutical News
Tags: Allergy, Biotechnology, Cancer, Cell, Headache, HIV/AIDS, Influenza, Malaria, New Drug Application, Pneumonia, Respiratory Disease, RNA, Tuberculosis, Virus